Pharmerging Global Market Report 2025

Description

Pharmerging describes the strategy of pharmaceutical companies expanding into emerging markets to achieve growth and reach new patient populations. It emphasizes capturing opportunities in countries with rapidly developing healthcare systems and rising demand for medicines.

The primary product types in pharmerging are pharmaceuticals, medical devices, diagnostics, biotechnology, and generics. Pharmaceuticals are substances or products used for diagnosing, treating, preventing, or managing diseases and medical conditions. They are applied for various indications such as lifestyle diseases, cancer, autoimmune disorders, infectious diseases, and others, and are available in multiple formulations including solid oral, liquid oral, injectable, topical, and others. Their applications span therapeutic, diagnostic, preventive, and research and development areas, and they are distributed through hospitals and clinics, retail pharmacies, online marketplaces, wholesale distributors, and direct-to-consumer channels.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The pharmerging market research report is one of a series of new reports from The Business Research Company that provides pharmerging market statistics, including pharmerging industry global market size, regional shares, competitors with a pharmerging market share, detailed pharmerging market segments, market trends and opportunities, and any further data you may need to thrive in the pharmerging industry. This emerging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharmerging market size has grown rapidly in recent years. It will grow from $2042.23 billion in 2024 to $2259.20 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to higher healthcare expenditure, increasing prevalence of chronic diseases, expansion of the middle-class population, growing urbanization, and greater awareness of health and wellness.

The pharmerging market size is expected to see rapid growth in the next few years. It will grow to $3339.19 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to rising demand for specialty medicines, expanding government healthcare initiatives, increasing healthcare awareness and literacy, and greater penetration of e-commerce in pharmaceuticals. Key trends in the forecast period include development of personalized medicine solutions, integration of digital health platforms, innovations in drug delivery systems, advancements in health financing models, and incorporation of supply chain technologies.

Rising healthcare spending is contributing to the expansion of the pharmerging market. Healthcare expenditure refers to the overall financial investment in medical services, treatments, healthcare facilities, research, and public health programs aimed at maintaining or enhancing health outcomes. This rise in spending is largely driven by an aging population that requires more frequent medical attention, treatments, and long-term care services. Increased healthcare expenditure supports the development of the pharmerging market by improving access to healthcare, enabling the expansion of infrastructure, and promoting the broader availability of cost-effective medications. For example, in December 2024, the Centers for Medicare & Medicaid Services, a US federal agency, reported that national health expenditures grew by 7.5 percent to reach $4.9 trillion in 2023, accounting for 17.6 percent of the gross domestic product. Furthermore, from 2023 to 2032, national health expenditures are projected to grow at an average annual rate of 5.6 percent, with the share of health spending in the gross domestic product expected to rise from 17.3 percent in 2022 to 19.7 percent in 2032. This upward trend in healthcare spending is fueling the growth of the pharmerging market.

Companies in the pharmerging market are focusing on the development of advanced treatments such as combination drug therapies to manage complex diseases and improve patient outcomes. Combination therapies involve the use of two or more active pharmaceutical ingredients within a single treatment plan to enhance therapeutic effects and target multiple aspects of a disorder simultaneously. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based contract development and manufacturing company, introduced Rabeprazole and Levosulpiride sustained-release capsules, a formulation approved by the Drug Controller General of India for the treatment of gastroesophageal reflux disease and other gastrointestinal disorders. The capsules combine Rabeprazole, which reduces stomach acid production, with Levosulpiride, which enhances stomach and intestinal movement to prevent acid reflux. This dual approach provides effective relief by addressing both acid suppression and improved gastrointestinal motility.

In November 2022, Biocon Limited, a biopharmaceutical company based in India, acquired the global biosimilars business of Viatris Inc. for an undisclosed amount. Through this acquisition, Biocon aims to reinforce its global standing in the biosimilars segment by expanding its presence, increasing access to affordable therapies, and accelerating growth through product launches and a broader international footprint. Viatris Inc. is a US-based pharmaceutical company focused on delivering affordable medication solutions in pharmerging regions.

Major players in the pharmerging market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, GE Healthcare Technologies Inc., Alembic Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Limited, Lupin Limited, and Beximco Pharmaceuticals Ltd.

North America was the largest region in the pharmerging market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharmerging report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pharmerging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharmerging market consists of revenues earned by entities by providing services such as contract research and manufacturing services (CRAMS), diagnostic testing and healthcare services, distribution and retail pharmacy operations, and the supply of medical devices and equipment. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmerging market also includes sales of over-the-counter (OTC) medicines, vaccines, biologics and biosimilars, and personal care and wellness products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmerging Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmerging market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharmerging ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmerging market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Pharmaceuticals; Medical Devices; Diagnostics; Biotechnology; Generics
2) By Indication: Lifestyle Diseases; Cancer And Autoimmune Diseases; Infectious Diseases; Other Indications
3) By Formulation: Solid Oral; Liquid Oral; Injectable; Topical; Other Formulation Types
4) By Application: Therapeutic; Diagnostic; Preventive; Research And Development
5) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Online Marketplaces; Wholesale Distributors; Direct-To-Consumer
Subsegments:
1) By Pharmaceuticals: Small Molecule Drugs; Biological Drugs; Over The Counter Drugs; Patented Drugs; Branded Generics; Vaccines
2) By Medical Devices: Diagnostic Imaging Devices; Surgical Instruments; Patient Monitoring Devices; Therapeutic Devices; Implantable Devices
3) By Diagnostics: In Vitro Diagnostics; Molecular Diagnostics; Imaging Diagnostics; Point Of Care Testing; Companion Diagnostics; Digital Diagnostics
4) By Biotechnology: Genomic Medicine; Cell Therapy; Gene Therapy; Monoclonal Antibodies; Biosimilars
5) By Generics: Oral Solid Dosage Generics; Injectable Generics; Topical Generics; Inhalable Generics; Ophthalmic Generics; Transdermal Generics
Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb; AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; GE Healthcare Technologies Inc.; Alembic Ltd.; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Limited; Aurobindo Pharma Limited; Dr. Reddy's Laboratories Ltd.; Cipla Limited; Aspen Pharmacare Holdings Limited; Zydus Lifesciences Limited; Lupin Limited; Beximco Pharmaceuticals Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r38604

1. Executive Summary

2. Pharmerging Market Characteristics

3. Pharmerging Market Trends And Strategies

4. Pharmerging Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Pharmerging Growth Analysis And Strategic Analysis Framework

5.1. Global Pharmerging PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Pharmerging Market Growth Rate Analysis
5.4. Global Pharmerging Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Pharmerging Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Pharmerging Total Addressable Market (TAM)

6. Pharmerging Market Segmentation

6.1. Global Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceuticals
Medical Devices
Diagnostics
Biotechnology
Generics
6.2. Global Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lifestyle Diseases
Cancer And Autoimmune Diseases
Infectious Diseases
Other Indications
6.3. Global Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Solid Oral
Liquid Oral
Injectable
Topical
Other Formulation Types
6.4. Global Pharmerging Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutic
Diagnostic
Preventive
Research And Development
6.5. Global Pharmerging Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Retail Pharmacies
Online Marketplaces
Wholesale Distributors
Direct-To-Consumer
6.6. Global Pharmerging Market, Sub-Segmentation Of Pharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Drugs
Biological Drugs
Over The Counter Drugs
Patented Drugs
Branded Generics
Vaccines
6.7. Global Pharmerging Market, Sub-Segmentation Of Medical Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostic Imaging Devices
Surgical Instruments
Patient Monitoring Devices
Therapeutic Devices
Implantable Devices
6.8. Global Pharmerging Market, Sub-Segmentation Of Diagnostics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
In Vitro Diagnostics
Molecular Diagnostics
Imaging Diagnostics
Point Of Care Testing
Companion Diagnostics
Digital Diagnostics
6.9. Global Pharmerging Market, Sub-Segmentation Of Biotechnology, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genomic Medicine
Cell Therapy
Gene Therapy
Monoclonal Antibodies
Biosimilars
6.10. Global Pharmerging Market, Sub-Segmentation Of Generics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Solid Dosage Generics
Injectable Generics
Topical Generics
Inhalable Generics
Ophthalmic Generics
Transdermal Generics

7. Pharmerging Market Regional And Country Analysis

7.1. Global Pharmerging Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Pharmerging Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pharmerging Market

8.1. Asia-Pacific Pharmerging Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pharmerging Market

9.1. China Pharmerging Market Overview
9.2. China Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pharmerging Market

10.1. India Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pharmerging Market

11.1. Japan Pharmerging Market Overview
11.2. Japan Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pharmerging Market

12.1. Australia Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pharmerging Market

13.1. Indonesia Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pharmerging Market

14.1. South Korea Pharmerging Market Overview
14.2. South Korea Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pharmerging Market

15.1. Western Europe Pharmerging Market Overview
15.2. Western Europe Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pharmerging Market

16.1. UK Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pharmerging Market

17.1. Germany Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pharmerging Market

18.1. France Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pharmerging Market

19.1. Italy Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pharmerging Market

20.1. Spain Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pharmerging Market

21.1. Eastern Europe Pharmerging Market Overview
21.2. Eastern Europe Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pharmerging Market

22.1. Russia Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pharmerging Market

23.1. North America Pharmerging Market Overview
23.2. North America Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pharmerging Market

24.1. USA Pharmerging Market Overview
24.2. USA Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pharmerging Market

25.1. Canada Pharmerging Market Overview
25.2. Canada Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pharmerging Market

26.1. South America Pharmerging Market Overview
26.2. South America Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pharmerging Market

27.1. Brazil Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pharmerging Market

28.1. Middle East Pharmerging Market Overview
28.2. Middle East Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pharmerging Market

29.1. Africa Pharmerging Market Overview
29.2. Africa Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pharmerging Market Competitive Landscape And Company Profiles

30.1. Pharmerging Market Competitive Landscape
30.2. Pharmerging Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

31. Pharmerging Market Other Major And Innovative Companies

31.1. AstraZeneca PLC
31.2. Novartis AG
31.3. GlaxoSmithKline plc
31.4. Eli Lilly and Company
31.5. GE Healthcare Technologies Inc.
31.6. Alembic Ltd.
31.7. Intas Pharmaceuticals Ltd.
31.8. Sun Pharmaceutical Industries Limited
31.9. Aurobindo Pharma Limited
31.10. Dr. Reddy's Laboratories Ltd.
31.11. Cipla Limited
31.12. Aspen Pharmacare Holdings Limited
31.13. Zydus Lifesciences Limited
31.14. Lupin Limited
31.15. Beximco Pharmaceuticals Ltd.

32. Global Pharmerging Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharmerging Market

34. Recent Developments In The Pharmerging Market

35. Pharmerging Market High Potential Countries, Segments and Strategies

35.1 Pharmerging Market In 2029 - Countries Offering Most New Opportunities
35.2 Pharmerging Market In 2029 - Segments Offering Most New Opportunities
35.3 Pharmerging Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer